Ireland
--:--IST
Recruiting Phase 2

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

NCT07288320 · tracked via the Priya Life Science USA tracker
Phase
Phase 2
Started
2025-12-24
Last updated
2026-09-29

Condition(s) studied

Bipolar I DisorderMania

Investigational drug(s) / intervention(s)

NBI-1117568 →Placebo

NBI-1117568: Oral administration

Placebo: Oral administration

Study summary

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Key Inclusion Criteria: * Participant has a primary diagnosis of bipolar I disorder. * The participant has had at least 1 prior documented manic episode that required treatment. * The participant is experiencing an acute manic episode or manic episode with mixed features, with or without psychotic symptoms. Key Exclusion Criteria: * Any unstable or poorly controlled medical condition or chronic disease (including history of neurological, hepatic, renal, cardiovascular, gastrointestinal, pulmonary, autoimmune, or endocrine disease that may affect study participation or results), or malignancy within 90 days before the start of screening. * Primary diagnosis is not bipolar I disorder. * History of clozapine treatment for treatment-resistant psychosis. * History of psychiatric hospitalization(s) for ≥30 consecutive days during the 90 days before the start of screening. Note: Additional inclusion/exclusion criteria may apply, per protocol.

Primary outcome measure(s)

  • Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Day 21 — Baseline, Day 21

Trial sites (11)

FacilityCityRegionStatus
Neurocrine Clinical Site Little Rock Arkansas Recruiting
Neurocrine Clinical Site Cerritos California Recruiting
Neurocrine Clinical Site Garden Grove California Recruiting
Neurocrine Clinical Site San Diego California Recruiting
Neurocrine Clinical Site Hollywood Florida Recruiting
Neurocrine Clinical Site Atlanta Georgia Recruiting
Neurocrine Clinical Site Gaithersburg Maryland Recruiting
Neurocrine Clinical Site Marlton New Jersey Recruiting
Neurocrine Clinical Site Staten Island New York Recruiting
Neurocrine Clinical Site Austin Texas Recruiting
Neurocrine Clinical Site Houston Texas Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07288320 on ClinicalTrials.gov ↗ ← All trials in the USA